Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
出版年份 2021 全文链接
标题
Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
作者
关键词
-
出版物
Diabetes Therapy
Volume 12, Issue 3, Pages 843-861
出版商
Springer Science and Business Media LLC
发表日期
2021-02-18
DOI
10.1007/s13300-021-01011-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
- (2020) Rod S. Taylor et al. GASTROENTEROLOGY
- Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
- (2020) Gianluca Svegliati-Baroni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2020) Hoda Taheri et al. ADVANCES IN THERAPY
- Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
- (2020) Alessandro Mantovani et al. GUT
- SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
- (2020) Shih-Chieh Shao et al. BMJ Open Diabetes Research & Care
- HOMA-IR is an independent predictor of advanced liver fibrosis in nondiabetic nonalcoholic fatty liver disease
- (2019) Hideki Fujii et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
- (2019) Peter J. Eddowes et al. GASTROENTEROLOGY
- Fat and Fibrosis: Does Empagliflozin Impair the Progression of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus?
- (2019) Reenam S. Khan et al. DIGESTIVE DISEASES AND SCIENCES
- Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
- (2019) Lee-Lee Lai et al. DIGESTIVE DISEASES AND SCIENCES
- Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
- (2019) Yoshitaka Arase et al. CLINICAL DRUG INVESTIGATION
- Metabolic Syndrome Is Associated With Advanced Liver Fibrosis Among Pediatric Patients With Non-alcoholic Fatty Liver Disease
- (2019) Yi-Wen Ting et al. Frontiers in Pediatrics
- Increased Hemoglobin A1c Correlates with Increased Liver Stiffness in a Mexican-American Population
- (2018) GORDON P. WATT et al. DIABETES
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus
- (2018) Noboru Kurinami et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
- (2018) Takashi Sasaki et al. Journal of Diabetes Investigation
- Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2018) Masanori Shimizu et al. DIABETES OBESITY & METABOLISM
- Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
- (2018) Teruki Miyake et al. Open Medicine
- Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non-alcoholic fatty liver disease
- (2018) Kenichi Tanaka et al. HEPATOLOGY RESEARCH
- Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
- (2017) Akio Ohta et al. EXPERT OPINION ON PHARMACOTHERAPY
- Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
- (2017) Yuya Seko et al. JOURNAL OF GASTROENTEROLOGY
- Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
- (2017) Yong-ho Lee et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan
- (2017) Dominique Roulot et al. LIVER INTERNATIONAL
- Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
- (2017) Wenjie Dai et al. MEDICINE
- Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study
- (2017) Yi-Hao Yen et al. PLoS One
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
- (2017) Liang Xu et al. EBioMedicine
- Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States
- (2017) Michael H. Le et al. PLoS One
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Clinical relevance of dual-energy X-ray absorptiometry (DXA) as a simultaneous evaluation of fatty liver disease and atherosclerosis in patients with type 2 diabetes
- (2016) Ryotaro Bouchi et al. Cardiovascular Diabetology
- Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors
- (2016) Takamasa Ohki et al. CLINICAL DRUG INVESTIGATION
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
- (2016) Simon A. Hawley et al. DIABETES
- Pathophysiology of Non Alcoholic Fatty Liver Disease
- (2016) Salvatore Petta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
- (2016) Giovanni Targher et al. JOURNAL OF HEPATOLOGY
- Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks
- (2016) Lawrence Blonde et al. POSTGRADUATE MEDICINE
- Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review
- (2016) Tyler J Severson et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
- (2016) Jason H Y Wu et al. Lancet Diabetes & Endocrinology
- Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
- (2016) Chikara Komiya et al. PLoS One
- Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
- (2015) Ian J Neeland et al. Diabetes & Vascular Disease Research
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Factors associated with significant liver fibrosis assessed using transient elastography in general population
- (2015) Seng Chan You WORLD JOURNAL OF GASTROENTEROLOGY
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
- (2013) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes
- (2013) Iliana Doycheva et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- NAFLD—the next global epidemic
- (2013) Katrina Ray Nature Reviews Gastroenterology & Hepatology
- Liver and diabetes. A vicious circle
- (2012) Paola Loria et al. HEPATOLOGY RESEARCH
- Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study)
- (2011) Françoise Degos et al. JOURNAL OF HEPATOLOGY
- Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS HCEP-23 study
- (2011) Jean-Pierre Zarski et al. JOURNAL OF HEPATOLOGY
- The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact
- (2011) Esther Phielix et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
- (2010) Giovanni Targher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Controlled Attenuation Parameter (CAP): A Novel VCTE™ Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes
- (2010) Magali Sasso et al. ULTRASOUND IN MEDICINE AND BIOLOGY
- Thiazolidinediones and the liver in humans
- (2009) Hannele Yki-Järvinen CURRENT OPINION IN LIPIDOLOGY
- The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease
- (2009) Stergios A. Polyzos et al. DIABETES OBESITY & METABOLISM
- Magnetic Resonance Elastography for the Noninvasive Staging of Liver Fibrosis
- (2008) Laurent Huwart et al. GASTROENTEROLOGY
- Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis
- (2008) Valerio Nobili et al. HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started